Ataluren is for the treatment of patients with genetic disorders that arise from a type of genetic mutation known as a nonsense mutation. Read the ataluren overview to learn more.

Ataluren for nmDMD:  Phase 3 study (041), recruiting

More information on this trial can be found at or by clicking here.

Additional information about ataluren clinical trials can be found at or by contacting Patient and Professional Advocacy at (866) 282-5873, (908) 912-9256 or

By selecting Confirm, you are leaving the PTC Therapeutics U.S. website. This external link is provided for your convenience. Please note that external links or web sites may not be controlled by PTC Therapeutics, and thus not subject to our Privacy policy and Terms of use.

Thank you for visiting our site.
Cancel Confirm
This site uses cookies to store information on your computer.
Cancel Continue